Search This Blog

Tuesday, April 14, 2026

Piper Sandler upgrades Biogen to Overweight, raises target to $214 on Apellis acquisition

 

Piper Sandler upgrades Biogen to Overweight, raises target to $214 on Apellis acquisition

  • Piper Sandler says Apellis acquisition should help offset declines in Biogen's legacy multiple sclerosis franchise.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)